Novadiscovery, Lyon, France.
Department of Biostatistics, Centre Léon Bérard, Lyon, France.
PLoS One. 2021 Oct 11;16(10):e0258093. doi: 10.1371/journal.pone.0258093. eCollection 2021.
In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm. RCTs emerged mid-last century as the gold standard for assessing efficacy, becoming the cornerstone of the value of new therapies, yet their ethical grounds are a matter of debate. We introduce the concept of unnecessary participants in RCTs, the sum of non-informative participants and non-responders. The non-informative participants are considered not informative with respect to the efficacy measured in the trial in contrast to responders who carry all the information required to conclude on the treatment's efficacy. The non-responders present the event whether or not they are treated with the experimental treatment. The unnecessary participants carry the burden of having to participate in a clinical trial without benefiting from it, which might include experiencing side effects. Thus, these unnecessary participants carry the ethical loss that is inherent to the RCT methodology. On the contrary, responders to the experimental treatment bear its entire efficacy in the RCT. Starting from the proportions observed in a real placebo-controlled trial from the literature, we carried out simulations of RCTs progressively increasing the proportion of responders up to 100%. We show that the number of unnecessary participants decreases steadily until the RCT's ethical loss reaches a minimum. In parallel, the trial sample size decreases (presumably its cost as well), although the trial's statistical power increases as shown by the increase of the chi-square comparing the event rates between the two arms. Thus, we expect that increasing the proportion of responders in RCTs would contribute to making them more ethically acceptable, with less false negative outcomes.
为了提出更精确的定义并探讨如何减少随机对照临床试验(RCT)中的伦理损失,我们着手确定那些不能证明实验组治疗优于对照组的试验参与者。RCT 是在上世纪中叶作为评估疗效的金标准出现的,成为新疗法价值的基石,但它们的伦理基础一直存在争议。我们引入 RCT 中不必要参与者的概念,即无信息参与者和无应答者的总和。与应答者相比,无信息参与者被认为对试验中测量的疗效没有信息,应答者携带得出治疗效果所需的所有信息。无应答者无论是否接受实验治疗都会出现该事件。不必要的参与者承担了参与临床试验但没有从中受益的负担,这可能包括经历副作用。因此,这些不必要的参与者承担了 RCT 方法固有的伦理损失。相反,对实验治疗有反应的参与者承担了 RCT 中的全部疗效。从文献中实际安慰剂对照试验中观察到的比例出发,我们进行了 RCT 模拟,逐步增加应答者的比例直至 100%。我们表明,不必要参与者的数量稳步减少,直到 RCT 的伦理损失达到最小值。与此同时,试验样本量减少(大概还有其成本),尽管试验的统计功效随着两个臂之间事件率的卡方比较的增加而增加。因此,我们预计增加 RCT 中应答者的比例将有助于使它们更具伦理可接受性,减少假阴性结果。